{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:18:59Z","timestamp":1787613539317,"version":"build-2736575974"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Kontextfaktoren wie Komorbidit\u00e4ten, Biomarker und bildgebende Verfahren werden st\u00e4rker in die kardiovaskul\u00e4re Risiko-Stratifizierung integriert und erm\u00f6glichen eine pr\u00e4zisere Identifikation von Patienten, die von einer lipidsenkenden Therapie besonders profitieren.<\/jats:p>\n                  <jats:p>F\u00fcr alle Patienten wird eine Intensivierung der lipidsenkenden Therapie empfohlen. Kombinationstherapien sollen fr\u00fchzeitig eingesetzt werden.<\/jats:p>\n                  <jats:p>Ein Gro\u00dfteil der in Fachinformationen aufgef\u00fchrten Nebenwirkungen l\u00e4sst sich nicht kausal auf eine Statintherapie zur\u00fcckf\u00fchren und ist in 9 von 10 F\u00e4llen durch einen Nocebo-Effekt erkl\u00e4rt.<\/jats:p>\n                  <jats:p>Die kumulative lebenszeitliche LDL-Cholesterin-Exposition ist eine zentrale Determinante des kardiovaskul\u00e4ren Risikos. Bei effektiver lipidsenkender Therapie ist eine Ann\u00e4herung der Lebenserwartung an die Allgemeinbev\u00f6lkerung m\u00f6glich. Entscheidend sind eine fr\u00fche Diagnose und Therapie. Ein Screening f\u00fcr LDL-Cholesterin im Kindesalter ist sinnvoll.<\/jats:p>\n                  <jats:p>Derzeit wird eine einmalige Bestimmung zur Risiko-Bestimmung empfohlen. RNA-basierte Therapien erm\u00f6glichen ausgepr\u00e4gte Senkungen des Lipoproteins(a); der klinische Nutzen wird derzeit in gro\u00dfen Endpunktstudien untersucht.<\/jats:p>\n                  <jats:p>Neue Ans\u00e4tze, insbesondere gegen Apolipoprotein C-III, erm\u00f6glichen eine potente Senkung bei schwerer Hypertriglyzerid\u00e4mie.<\/jats:p>","DOI":"10.1055\/a-2676-2694","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:32:26Z","timestamp":1787610746000},"page":"961-967","source":"Crossref","is-referenced-by-count":0,"title":["Neue Strategien der Lipidtherapie: Implikationen des ESC\/EAS-Updates 2025"],"prefix":"10.1055","volume":"151","author":[{"given":"Tobias","family":"Schneider","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Leipzig, Deutschland","place":["Leipzig"],"department":["Klinik und Poliklinik f\u00fcr Kardiologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Leipzig, Deutschland","place":["Leipzig"],"department":["Klinik und Poliklinik f\u00fcr Kardiologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"32","key":"ref1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"BA Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","author":"F Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"01","key":"ref3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12181-026-00795-7","article-title":"Management von Fettstoffwechselst\u00f6rungen \u2013 DGK-Kommentar zu den Leitlinien der ESC\/EAS (2025)","volume":"20","author":"U Laufs","year":"2026","journal-title":"Kardiologie"},{"issue":"13","key":"ref5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk","volume":"76","author":"MJ Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00392-025-02686-5","article-title":"Treatment pathways of lipid-lowering therapies in Germany 2016\u20132022","volume":"115","author":"JL Katzmann","year":"2025","journal-title":"Clin Res Cardiol"},{"issue":"15","key":"ref7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"SE Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(25)01578-8","article-title":"Electronic address: ctt@ndph.ox.ac.uk; Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials","volume":"407","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2026","journal-title":"Lancet"},{"issue":"09","key":"ref9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s11886-022-01729-x","article-title":"SAMSON and the Nocebo Effect: Management of Statin Intolerance","volume":"24","author":"A Krishnamurthy","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"ref10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/eurheartj\/ehae912","article-title":"Ages at coronary heart disease and death in familial hypercholesterolaemia: a Danish nationwide study spanning 44 years","volume":"46","author":"J Reeh","year":"2025","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.atherosclerosis.2018.06.858","article-title":"Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review","volume":"277","author":"U Groselj","year":"2018","journal-title":"Atherosclerosis"},{"issue":"03","key":"ref12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/MOL.0000000000000926","article-title":"Familial hypercholesterolemia in children and the importance of early treatment","volume":"35","author":"SE van den Bosch","year":"2024","journal-title":"Curr Opin Lipidol"},{"issue":"03","key":"ref13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/eurpub\/ckac007","article-title":"Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study","volume":"32","author":"V Sanin","year":"2022","journal-title":"Eur J Public Health"},{"issue":"02","key":"ref14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in Patients without a Previous Myocardial Infarction or Stroke","volume":"394","author":"EA Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1727918","article-title":"Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction","volume":"12","author":"IS Alhomoud","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"18","key":"ref16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"MS Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"02","key":"ref17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/ph18020147","article-title":"Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review","volume":"18","author":"JM Zimodro","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"21","key":"ref18","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"A Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"01","key":"ref19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"DL Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"06","key":"ref20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"JL Witztum","year":"2019","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2676-2694.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:32:31Z","timestamp":1787610751000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2676-2694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2676-2694","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}